The Activated Phagocyte of Polycythemia Vera

The activated phagocyte of polycythemia vera.

Leukocytes isolated from patients with polycythemia vera (PCV), a panmyelopathy, have increased metabolic activity during the resting and phagocytizing states. Phagocytes from patients with PCV were studied by counting particle ingestion, measuring hexose monophosphate shunt (HMP) activity by the conversion of glucose1-’4C tr, ‘4CO2, and determining 02 consumption and nitroblue tetrazolium (NBT...

Treatment of polycythemia vera.

BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...

Pathogenesis of polycythemia vera.

BACKGROUND AND OBJECTIVE Polycythemia vera (PV) is an acquired clonal myeloproliferative disorder characterized by increased production of mature red cells. We still lack a molecular target responsible for this disorder; however, recent investigations have focused on a number of molecules involved in signal transduction pathways mediated by erythropoietin (Epo) and other growth factors. Here we...

Muramidase in polycythemia vera.

Polycythemia vera: a review.

Polycythemia vera (PV) is a clonal stem cell disorder characterized by increased erythrocyte production. Its etiology is not fully understood, and hemorrhage, thrombosis, and hyperviscosity may occur at any time during the course of this disorder. Treatment depends on the most affected cell type, duration and severity of the condition, and patient age. PV treatment can involve phlebotomy, admin...